ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Magistroni, Vera ^a   Mologni, Luca ^a   Sanselicio, Stefano ^a,f   Reid, James Frances ^b,c   Redaelli, Sara ^a   Piazza, Rocco ^a   Viltadi, Michela ^a   Bovo, Giorgio ^d   Strada, Guido ^e   Grasso, Marco ^d   Gariboldi, Manuela ^b,c   Gambacorti Passerini, Carlo ^a,d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e Urology Division   (Italy)

^f UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLIN B1; IDARUBICIN; PACLITAXEL; PROTEIN KINASE PIM 1; TAXANE DERIVATIVE;

ANEUPLOIDY; ARTICLE; BINDING KINETICS; CANCER CHEMOTHERAPY; CANCER STAGING; CARCINOGENESIS; CARCINOGENICITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME INDUCTION; ERG GENE; EWS GENE; FUS GENE; FUSION GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC CODE; GENETIC STABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; STABLE EXPRESSION; TRUNCATED ERG GENE; TUMOR GENE; UPREGULATION;

EID: 82355193787     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028162     Document Type: Article

References (55)

1. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrozek K, et al. (2005) Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 23: 9234-9242.
2. Baldus CD, Burmeister T, Martus P, Schwartz S, Gokbuget N, et al. (2006) High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 24: 4714-4720.
3. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, et al. (1992) Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359: 162-165.
4. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, et al. (1994) A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 6: 146-151.
5. Shimizu K, Ichikawa H, Tojo A, Kaneko Y, Maseki N, et al. (1993) An ets-related gene, ERG, is rearranged in human myeloid leukemia with t(16;21) chromosomal translocation. Proc Natl Acad Sci U S A 90: 10280-10284.
6. Ichikawa H, Shimizu K, Hayashi Y, Ohki M, (1994) An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. Cancer Res 54: 2865-2868.
7. Panagopoulos I, Aman P, Fioretos T, Hoglund M, Johansson B, et al. (1994) Fusion of the FUS gene with ERG in acute myeloid leukemia with t(16;21)(p11;q22). Genes Chromosomes Cancer 11: 256-262.
8. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, et al. (1993) Combinatorial generation of variable fusion proteins in the Ewing family of tumours. Embo J 12: 4481-4487.
9. Kong XT, Ida K, Ichikawa H, Shimizu K, Ohki M, et al. (1997) Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. Blood 90: 1192-1199.
10. Giovannini M, Biegel JA, Serra M, Wang JY, Wei YH, et al. (1994) EWS-erg and EWS-Fli1 fusion transcripts in Ewing's sarcoma and primitive neuroectodermal tumors with variant translocations. J Clin Invest 94: 489-496.
11. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
12. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, et al. (2007) Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26: 2667-2673.
13. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, et al. (2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 41: 524-526.
14. Codrington R, Pannell R, Forster A, Drynan LF, Daser A, et al. (2005) The Ews-ERG fusion protein can initiate neoplasia from lineage-committed haematopoietic cells. PLoS Biol 3: e242.
15. Ichikawa H, Shimizu K, Katsu R, Ohki M, (1999) Dual transforming activities of the FUS (TLS)-ERG leukemia fusion protein conferred by two N-terminal domains of FUS (TLS). Mol Cell Biol 19: 7639-7650.
16. Pereira DS, Dorrell C, Ito CY, Gan OI, Murdoch B, et al. (1998) Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells. Proc Natl Acad Sci U S A 95: 8239-8244.
17. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, et al. (2009) ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A 106: 12465-12470.
18. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, et al. (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177-188.
19. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, et al. (2008) A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 105: 2105-2110.
20. Carver BS, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, et al. (2009) ETS rearrangements and prostate cancer initiation. Nature 457: E1; discussion E2-3.
21. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, et al. (2011) Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer. Cancer Cell 19: 664-678.
22. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, et al. (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822-826.
23. Valdman A, Fang X, Pang ST, Ekman P, Egevad L, (2004) Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 60: 367-371.
24. Beier UH, Weise JB, Laudien M, Sauerwein H, Gorogh T, (2007) Overexpression of Pim-1 in head and neck squamous cell carcinomas. Int J Oncol 30: 1381-1387.
25. Peltola K, Hollmen M, Maula SM, Rainio E, Ristamaki R, et al. (2009) Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia 11: 629-636.
26. Reiser-Erkan C, Erkan M, Pan Z, Bekasi S, Giese NA, et al. (2008) Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther 7: 1352-1359.
27. Babel I, Barderas R, Diaz-Uriarte R, Martinez-Torrecuadrada JL, Sanchez-Carbayo M, et al. (2009) Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics 8: 2382-2395.
28. Roh M, Gary B, Song C, Said-Al-Naief N, Tousson A, et al. (2003) Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res 63: 8079-8084.
29. Roh M, Song C, Kim J, Abdulkadir SA, (2005) Chromosomal instability induced by Pim-1 is passage-dependent and associated with dysregulation of cyclin B1. J Biol Chem 280: 40568-40577.
30. Roh M, Franco OE, Hayward SW, van der Meer R, Abdulkadir SA, (2008) A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells. PLoS One 3: e2572.
31. Birdsey GM, Dryden NH, Amsellem V, Gebhardt F, Sahnan K, et al. (2008) Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 111: 3498-3506.
32. Nawijn MC, Alendar A, Berns A, (2010) For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 11: 23-34.
33. Kim J, Roh M, Abdulkadir SA, (2010) Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer 10: 248.
34. Kunderfranco P, Mello-Grand M, Cangemi R, Pellini S, Mensah A, et al. (2010) ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One 5: e10547.
35. Xie Y, Xu K, Dai B, Guo Z, Jiang T, et al. (2006) The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 25: 70-78.
36. Zemskova M, Sahakian E, Bashkirova S, Lilly M, (2008) The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem 283: 20635-20644.
37. Xie Y, Xu K, Linn DE, Yang X, Guo Z, et al. (2008) The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem 283: 3349-3356.
38. Cibull TL, Jones TD, Li L, Eble JN, Ann Baldridge L, et al. (2006) Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol 59: 285-288.
39. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, et al. (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31: 882-888.
40. Mumenthaler SM, Ng PY, Hodge A, Bearss D, Berk G, et al. (2009) Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther 8: 2882-2893.
41. Chen J, Kobayashi M, Darmanin S, Qiao Y, Gully C, et al. (2009) Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene 28: 2581-2592.
42. Bhattacharya N, Wang Z, Davitt C, McKenzie IF, Xing PX, et al. (2002) Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 111: 80-95.
43. Torres EM, Williams BR, Amon A, (2008) Aneuploidy: cells losing their balance. Genetics 179: 737-746.
44. Yang L, Embree LJ, Hickstein DD, (2000) TLS-ERG leukemia fusion protein inhibits RNA splicing mediated by serine-arginine proteins. Mol Cell Biol 20: 3345-3354.
45. Zou J, Ichikawa H, Blackburn ML, Hu HM, Zielinska-Kwiatkowska A, et al. (2005) The oncogenic TLS-ERG fusion protein exerts different effects in hematopoietic cells and fibroblasts. Mol Cell Biol 25: 6235-6246.
46. Chu Q, Ling MT, Feng H, Cheung HW, Tsao SW, et al. (2006) A novel anticancer effect of garlic derivatives: inhibition of cancer cell invasion through restoration of E-cadherin expression. Carcinogenesis 27: 2180-2189.
47. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, et al. (2005) Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105: 1759-1767.
48. Willems E, Mateizel I, Kemp C, Cauffman G, Sermon K, et al. (2006) Selection of reference genes in mouse embryos and in differentiating human and mouse ES cells. Int J Dev Biol 50: 627-635.
49. Van Orman JR, Weihrauch D, Warltier DC, Lough J, (2009) Myocardial interstitial fluid inhibits proliferation and cardiomyocyte differentiation in pluripotent embryonic stem cells. Am J Physiol Heart Circ Physiol 297: H1369-1376.
50. Diecke S, Quiroga-Negreira A, Redmer T, Besser D, (2008) FGF2 signaling in mouse embryonic fibroblasts is crucial for self-renewal of embryonic stem cells. Cells Tissues Organs 188: 52-61.
51. Sahlberg C, Peltonen E, Lukinmaa PL, Alaluusua S, (2007) Dioxin alters gene expression in mouse embryonic tooth explants. J Dent Res 86: 600-605.
52. Diaz FJ, O'Brien MJ, Wigglesworth K, Eppig JJ, (2006) The preantral granulosa cell to cumulus cell transition in the mouse ovary: development of competence to undergo expansion. Dev Biol 299: 91-104.
53. Harb JG, Chyla BI, Huettner CS, (2008) Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis. Blood 111: 3760-3769.
54. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood 116: 3013-3022.
55. Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, et al. (2010) Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2. Cancer Res 70: 7253-7263.